[go: up one dir, main page]

SK168196A3 - Anti-hiv triple combination - Google Patents

Anti-hiv triple combination Download PDF

Info

Publication number
SK168196A3
SK168196A3 SK1681-96A SK168196A SK168196A3 SK 168196 A3 SK168196 A3 SK 168196A3 SK 168196 A SK168196 A SK 168196A SK 168196 A3 SK168196 A3 SK 168196A3
Authority
SK
Slovakia
Prior art keywords
hiv
combination
zidovudine
lamivudine
loviride
Prior art date
Application number
SK1681-96A
Other languages
English (en)
Slovak (sk)
Inventor
Paulus A M Stoffels
Koenraad J L M Andries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SK168196A3 publication Critical patent/SK168196A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1681-96A 1994-07-01 1995-06-23 Anti-hiv triple combination SK168196A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201897 1994-07-01
PCT/EP1995/002462 WO1996001110A2 (fr) 1994-07-01 1995-06-23 Triple combinaison anti-vih

Publications (1)

Publication Number Publication Date
SK168196A3 true SK168196A3 (en) 1997-05-07

Family

ID=8217000

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1681-96A SK168196A3 (en) 1994-07-01 1995-06-23 Anti-hiv triple combination

Country Status (25)

Country Link
EP (1) EP0768881B1 (fr)
JP (1) JP2945481B2 (fr)
KR (1) KR100218495B1 (fr)
CN (1) CN1091599C (fr)
AP (1) AP9600896A0 (fr)
AT (1) ATE218867T1 (fr)
AU (1) AU693911B2 (fr)
BG (1) BG101175A (fr)
BR (1) BR9508201A (fr)
CA (1) CA2193489A1 (fr)
CZ (1) CZ375596A3 (fr)
DE (1) DE69527066T2 (fr)
EE (1) EE9600180A (fr)
FI (1) FI965292L (fr)
HU (1) HUT77720A (fr)
IL (1) IL114415A0 (fr)
MX (1) MX9700044A (fr)
MY (1) MY130597A (fr)
NO (1) NO965556D0 (fr)
OA (1) OA10341A (fr)
PL (1) PL317891A1 (fr)
SK (1) SK168196A3 (fr)
TW (1) TW401303B (fr)
WO (1) WO1996001110A2 (fr)
ZA (1) ZA955471B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942747A1 (fr) * 1996-08-26 1999-09-22 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)
EP0872233A1 (fr) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Médicaments antirétroviraux à biodisponibilité améliorée
EA005423B1 (ru) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
WO2010137027A1 (fr) 2009-05-27 2010-12-02 Hetero Research Foundation Formes pharmaceutiques solides de lamivudine s'administrant par voie orale
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger

Also Published As

Publication number Publication date
FI965292A7 (fi) 1996-12-31
JP2945481B2 (ja) 1999-09-06
EP0768881B1 (fr) 2002-06-12
BG101175A (bg) 1997-08-29
DE69527066T2 (de) 2003-02-13
AU693911B2 (en) 1998-07-09
EP0768881A2 (fr) 1997-04-23
HUT77720A (hu) 1998-07-28
KR100218495B1 (en) 1999-09-01
EE9600180A (et) 1997-06-16
MY130597A (en) 2007-07-31
NO965556L (no) 1996-12-23
TW401303B (en) 2000-08-11
ATE218867T1 (de) 2002-06-15
WO1996001110A2 (fr) 1996-01-18
JPH09507858A (ja) 1997-08-12
WO1996001110A3 (fr) 1996-02-22
AP9600896A0 (en) 1997-01-31
CA2193489A1 (fr) 1996-01-18
AU2924895A (en) 1996-01-25
DE69527066D1 (de) 2002-07-18
CN1091599C (zh) 2002-10-02
OA10341A (en) 1997-10-07
CN1151697A (zh) 1997-06-11
CZ375596A3 (en) 1997-04-16
FI965292A0 (fi) 1996-12-31
IL114415A0 (en) 1995-10-31
PL317891A1 (en) 1997-04-28
NO965556D0 (no) 1996-12-23
FI965292L (fi) 1996-12-31
HU9603627D0 (en) 1997-02-28
MX9700044A (es) 1997-04-30
BR9508201A (pt) 1997-11-11
ZA955471B (en) 1996-12-30

Similar Documents

Publication Publication Date Title
US20060229293A1 (en) Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
EP2083825A1 (fr) Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
EP0482081B1 (fr) Composition antivirale
AU2021261965A1 (en) Regimens for treating hiv infections and aids
Nelson et al. Emtricitabine (FTC) for the treatment of HIV infection
SK168196A3 (en) Anti-hiv triple combination
DE68914990T2 (de) Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
WO1997037661A1 (fr) Medicament de prevention et de traitement des infections virales
JPH02501220A (ja) 芳香族多環式ジオンを含有する抗ウイルス性薬剤及びレトロウイルス感染治療方法
US5541212A (en) Use of cimetidine for the control of retrovirus infections
Acosta et al. Agents for treating human immunodeficiency virus infection
Humphrey et al. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection
Merry et al. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients
AU716760B2 (en) Aids therapeutic composition
Kahn The clinical use of didanosine
RU2331420C2 (ru) Противовирусное средство (варианты) и способ лечения на его основе
CA2230086C (fr) Procede ameliorant l'activite biologique et antivirale d'inhibiteurs de proteases
Fletcher Current perspectives on antiretroviral therapy
Galasso Antiviral agents: a new beginning
DE3821676A1 (de) Verwendung von avaron oder avaron-derivaten in kombination mit 3'-azido-3'-deoxythymidin zur antiviralen therapie
Kessler et al. Therapy for Human Immunodeficiency Virus Infection—1989
NZ335639A (en) (R)-N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[(R)-2-(5-isoquinolyloxyacetyl)amino-3-methylthiopropanoyl] amino-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxyamide (KNI-272) an another agent for the treatment of AIDS
WO1998042349A1 (fr) Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus